Pharmacology of botulinum neurotoxins

Operative Techniques in Otolaryngology - Head and Neck Surgery

Volumn 15, Issue 2, 2004, Pages 81-85

  Aoki, K Roger ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROTRANSMITTER; SNARE PROTEIN;

ACETYLCHOLINE RELEASE; ANALGESIA; BACKACHE; CLOSTRIDIUM BOTULINUM; CRICOPHARYNGEUS MUSCLE; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DYSPHAGIA; DYSTONIA; EXOCYTOSIS; HEAD AND NECK DISEASE; HEADACHE; HUMAN; INHIBITION KINETICS; MIGRAINE; MOUSE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NECK PAIN; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPASTICITY; SWEAT GLAND DISEASE; TORTICOLLIS; XEROSTOMIA;

EID: 3242728815     PISSN: 10431810     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otot.2004.03.003     Document Type: Article

References (87)

1. Aoki K.R. Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions Eur J Neurol 8 suppl 5 2001 21-29
2. Aoki K.R. Botulinum toxin, a successful therapeutic protein Curr Med Chem 2004 (in press)
3. Brin M.F. Botulinum toxin: New and expanded indications Eur J Neurol 4 1997 59-66
4. Wheeler A.H. Goolkasian P. Gretz S.S. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome Spine 23 1998 1662-1666
5. Parameswaran M.S. Soliman A.M. Endoscopic botulinum toxin injection for cricopharyngeal dysphagia Ann Otol Rhinol Laryngol 111 2002 871-874
6. Eckardt A. Kuettner C. Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A Head Neck 25 2003 624-628
7. Hatheway C.L. Bacterial sources of clostridial neurotoxins in Simpson L.L. (ed): Botulinum Neurotoxin and Tetanus Toxin 1989 3-24 Academic San Diego
8. Das Gupta B.R. The structure of botulinum neurotoxin in Simpson L.L. (ed): Botulinum Neurotoxin and Tetanus Toxin 1989 53-67 Academic New York
9. Das Gupta B.R. Sugiyama H. Role of a protease in natural activation of Clostridium botulinum neurotoxin Infect Immun 6 1972 587-590
10. Sakaguchi G. Kozaki S. Ohishi I. Structure and function of botulinum toxins in Alouf J.E. (ed): Bacterial Protein Toxins 1984 435-443 Academic Press London
11. Sugii S. Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins Infect Immun 12 1975 1262-1270
12. Binz T. Kurazono H. Wille M. et al. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins J Biol Chem 265 1990 9153-9158
13. Niemann H. Molecular biology of clostridial neurotoxins in Alouf J.E. Freer J.H. (eds): Sourcebook of Bacterial Protein Toxins 1991 303-348 Academic London
14. Hutson R.A. Collins M.D. East A.K. et al. Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin Comparison with other clostridial neurotoxins Curr Microbiol 28 1994 101-110
15. Zhang L. Lin W.J. Li S. et al. Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain Gene 315 2003 21-32
16. Whelan S.M. Elmore M.J. Bodsworth N.J. et al. Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence Appl Environ Microbiol 58 1992 2345-2354
17. Montecucco C. Schiavo G. Structure and function of tetanus and botulinum neurotoxins Q Rev Biophys 28 1995 423-472
18. Lacy D.B. Stevens R.C. Sequence homology and structural analysis of the clostridial neurotoxins J Mol Biol 291 1999 1091-1104
19. Kurazono H. Mochida S. Binz T. et al. Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A J Biol Chem 267 1992 14721-14729
20. Simpson L.L. The action of botulinal toxin Rev Infect Dis 1 1979 656-662
21. Black J.D. Dolly J.O. Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems Neuroscience 23 1987 767-779
22. 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves J Cell Biol 103 1986 521-534
23. Dong M. Richards D.A. Goodnough M.C. et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells J Cell Biol 162 2003 1293-1303
24. Nishiki T. Kamata Y. Nemoto Y. et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes J Biol Chem 269 1994 10498-10503
25. O'Sullivan G.A. Mohammed N. Foran P.G. et al. Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues J Biol Chem 274 1999 36897-36904
26. Ishikawa H. Mitsui Y. Yoshitomi T. et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles Jpn J Ophthalmol 44 2000 106-109
27. Hohne-Zell B. Galler A. Schepp W. et al. Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffin-like cells Endocrinology 138 1997 5518-5526
28. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis J Cell Biol 103 1986 535-544
29. Pellizzari R. Rosseto O. Schiavo G. et al. Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses Philosoph Trans Royal Soc London Biol Sci 354 1999 259-268
30. Rossetto O. Seveso M. Caccin P. et al. Botulinum neurotoxins are metalloproteases specific for SNARE proteins involved in neuroexocytosis Curr Prob Dermatol 30 2002 117-125
31. Schiavo G. Santucci A. Das Gupta B.R. et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds FEBS Lett 335 1993 99-103
32. Schiavo G. Malizio C. Trimble W.S. et al. Botulinum G neurotoxin cleaves vamp/synaptobrevin at a single ala-ala peptide bond J Biol Chem 269 1994 20213-20216
33. Schiavo G. Rossetto O. Benfenati F. et al. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus Ann NY Acad Sci 710 1994 65-75
34. Schiavo G. Rossetto O. Catsicas S. et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E J Biol Chem 268 1993 23784-23787
35. Schiavo G. Rossetto O. Santucci A. et al. Botulinum neurotoxins are zinc proteins J Biol Chem 267 1992 23479-23483
36. Blasi J. Chapman E.R. Link E. et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 Nature 365 1993 160-163
37. Blasi J. Chapman E.R. Yamasaki S. et al. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin EMBO J 12 1993 4821-4828
38. Foran P.G. Mohammed N. Lisk G.O. et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons J Biol Chem 278 2003 1363-1371
39. Eleopra R. Tugnoli V. Caniatti M.L. et al. Neurophysiological study in man of the different action of the botulinum toxin type A, C and F Mov Disord 9 1994 143
40. Eleopra R. Serotypes C and E: Clinical trials results Mov Disord 15 2000 15-16
41. Sellin L.C. Thesleff S. Dasgupta B.R. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction Acta Physiol Scand 119 1983 127-133
42. Aoki K.R. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety Toxicon 40 2002 923-938
43. Sloop R.R. Cole B.A. Escutin R.O. Human response to botulinum toxin injection: type B compared with type A Neurology 49 1997 189-194
44. Matarasso S.L. Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides Dermatol Surg 29 2003 7-13
45. Lowe N.J. Yamauchi P.S. Lask G.P. et al. Botulinum toxins types A and B for brow furrows: Preliminary experiences with type B toxin dosing J Cosmet Laser Ther 4 2002 15-18
46. Eleopra R. Tugnoli V. Rossetto O. et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans Neurosci Lett 256 1998 135-138
47. Mezaki T. Kaji R. Kohara N. et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study Neurology 45 1995 506-508
48. Gelb D.J. Yoshimura D.M. Olney R.K. Change in pattern of muscle activity following botulinum toxin injections for torticollis Ann Neurol 29 1991 370-376
49. Duchen L.W. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin J Neurol Sci 14 1971 61-74
50. Angaut-D.-Petit Molgo J. Comella J.X. et al. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: Morphological and electrophysiological features Neuroscience 37 1990 799-808
51. de Paiva A. Meunier F.A. Molgo J. et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals Proc Natl Acad Sci USA 96 1999 3200-3205
52. Brin M.F. Blitzer A. Stewart C. et al. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: Review and technical aspects in Blitzer A. Brin M.F. Sasaki C.T. (eds): Neurological Disorders of the Larynx 1992 214-218 Thieme New York
53. Ludlow C.L. Hallett M. Sedory S.E. et al. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin in Berardelli A. Benecke R. Manfredi M. (eds): Motor Disturbances II 1990 273-278 Academic New York
54. Filippi G.M. Errico P. Santarelli R. et al. Botulinum A toxin effects on rat jaw muscle spindles Acta Otolaryngol 113 1993 400-404
55. Zwirner P. Murry T. Swenson M. et al. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: Acoustic, aerodynamic, and videoendoscopic findings Laryngoscope 102 1992 400-406
56. Rosales R.L. Arimura K. Takenaga S. et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection Muscle Nerve 19 1996 488-496
57. Tsui J.K.C. Eisen A. Stoessl A.J. et al. Double-blind study of botulinum toxin in spasmodic torticollis Lancet 2 1986 245-247
58. Silberstein S. Mathew N. Saper J. et al. BOTOX Migraine Clinical Research Group Botulinum toxin type A as a migraine preventive treatment Headache 40 2000 445-450
59. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders Headache 43 2003 853-860
60. Foster L. Clapp L. Erickson M. et al. Botulinum toxin A and chronic low back pain: A randomized, double-blind study Neurology 56 2001 1290-1293
61. Cui M. Khanijou S. Rubino J. et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain Pain 107 2004 125-133
62. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management Headache 43 suppl 2003 S9-S15
63. Durham P. Cady R. Cady R. Mechanism of botulinum toxin type-A inhibition of calcitonin gene-related peptide secretion from trigeminal nerve cells Cephalalgia 23 2003 690
64. Purkiss J. Welch M. Doward S. et al. Capsaicin-stimulated release of substance p from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms Biochem Pharmacol 59 2000 1403-1406
65. Welch M.J. Purkiss J.R. Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins Toxicon 38 2000 245-258
66. McMahon H.T. Foran P. Dolly J.O. et al. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkaphalin release from synaptosomes J Biol Chem 267 1992 21338-21343
67. Sanchez-Prieto J. Sihra T.S. Evans D. et al. Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes Eur J Biochem 165 1987 675-681
68. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice Toxicon 39 2001 1815-1820
69. Sugiyama H. Brenner S.L. Das Gupta B.R. Detection of Clostridium botulinum toxin by local paralysis elicited with intramuscular challenge Appl Microbiol 30 1975 420-423
70. Duchen L.W. Rogers M. Stolkin C. et al. Suppression of botulinum toxin-induced axonal sprouting in skeletal muscle by implantation of an extra nerve J Physiol (Lond) 248 1975 1P-2P
71. Aoki R. Francis J. Reynolds H. et al. Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model Neurology 60 5 suppl 1 2003 A212-A213
72. Buchman A.S. Comella C.L. Stebbins G.T. et al. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia Clin Neuropharmacol 16 1993 205-210
73. Eleopra R. Tugnoli V. Caniatti L. et al. Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion Neurology 46 1996 1158-1160
74. Ross M.H. Charness M.E. Sudarsky L. et al. Treatment of occupational cramp with botulinum toxin: Diffusion of toxin to adjacent noninjected muscles Muscle Nerve 20 1997 593-598
75. Brashear A. Lew M.F. Dykstra D.D. et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 53 1999 1439-1446
76. Brin M.F. Lew M.F. Adler C.H. et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 53 1999 1431-1438
77. Lew M.F. Adornato B.T. Duane D.D. et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia Neurology 49 1997 701-707
78. Poewe W. Deuschl G. Nebe A. et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport® J Neurol Neurosurg Psychiatry 64 1998 13-17
79. Hauser R.A. Comella C. Brashear A. et al. A randomized, multicenter, double-blind, placebo-controlled study of original Botox (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia [abstract] Mov Disord 15 suppl 2 2000 30-31
80. Naumann M. Yakovleff A. Durif F. BOTOX Cervical Dystonia Prospective Study Group A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia J Neurol 249 2002 57-63
81. Brashear A. McAfee A.L. Kuhn E.R. et al. Treatment with botulinum toxin type B for upper-limb spasticity Arch Phys Med Rehabil 84 2003 103-107
82. Opida C.L. Open-label study of Myobloc (botulinum toxin type B) in the treatment of post-whiplash headaches Naunyn Schmiedebergs Arch Pharmacol 365 suppl 2 2002 R3296
83. Dressler D. Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis Eur Neurol 49 2003 34-38
84. Bakheit A.M. Ward C.D. McLellan D.L. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: A report of two cases J Neurol Neurosurg Psychiatry 62 1997 198
85. Beseler-Soto B. Sanchez-Palomares M. Santos-Serrano L. et al. Iatrogenic botulism: A complication to be taken into account in the treatment of child spasticity Rev Neurol 37 2003 444-446
86. Bhatia K.P. Munchau A. Thompson P.D. et al. Generalised muscular weakness after botulinum toxin injections for dystonia: A report of three cases J Neurol Neurosurg Psychiatry 67 1999 90-93
87. Benecke R. Botulinum toxin for spasms and spasticity in the lower extremities in Jankovic J. Hallett M. (eds): Therapy with Botulinum Boxin 1994 557-565 Marcel Dekker New York